Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
15 June 2018
P-001516/2018
Answer given by Ms Malmström on behalf of the Commission

The Council Conclusions of June 2016 on ‘Strengthening the balance in the pharmaceutical systems in the European Union and its Member States’ invite the Commission to perform, among other things, an analysis of the impact of pharmaceutical incentives on innovation, availability and accessibility of medicinal products in the European Union. As part of this effort, a holistic, in-depth and evidence based analysis of those incentives has been carried out by an external consultant, Copenhagen Economics, contracted by the Commission. The final report of Copenhagen Economics is available on the website of the European Commission(1).

The Commission is aware of the submissions by Pharmaceutical Research and Manufacturers of America (PhRMA) and Biotechnology Innovation Organisation (BIO) in the context of stakeholder consultations on the 2018 Special 301 Report by the Office of the United States Trade Representative (USTR). The EU was not placed on the watch list in the report, neither does the report mention the matter brought up by PhRMA and BIO.

The Commission conducts its policy based on evidence, in consultation with the relevant stakeholders, in a transparent manner and independently of any administrative procedures carried out by third countries. It will engage in further discussions with all stakeholders about the outcomes of this study and analysis.

(1)https://ec.europa.eu/docsroom/documents/29521

Last updated: 18 June 2018Legal notice